SerpinB3 protein in acute respiratory distress
Part of Lungs & breathing clinical trials.
This study looks at a protein called SerpinB3 and its role in severe lung inflammation (ARDS). It may help doctors understand how ARDS develops and find new ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with ARDS (a type of severe lung injury).
- You must be on a breathing machine (mechanical ventilation).
- You must be 18 years or older.
- You must not be pregnant.
- You must not have certain chronic skin, lung, or inflammatory diseases.
- You must not have any of the listed cancers (like certain lung, breast, or liver cancers).
- You must not have a history of smoking (active or secondhand).
- You must be willing to have a bronchoscopy and BAL (a procedure to collect fluid from your lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
This trial looks at how the immune system might cause severe breathing problems (ARDS). It may help doctors understand what happens in the lungs during this condition and find better ways to treat it.
This study is for patients in the ICU with ARDS (a severe lung condition). It looks at biomarkers (special substances in your blood) to help understand different types of ARDS. You do not receive any treatment, but you help researchers learn more about the disease.
This study looks at how a specific pathway (called RSPO3/SDC-1) helps repair damaged lungs in older adults with ARDS. It may help doctors find new ways to improve recovery after severe breathing problems.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This study looks at two substances in saliva and lung fluid—called IL-6 and TNF-α—in children with severe lung failure (ARDS) who are on a breathing machine. Measuring these markers may help doctors better understand the condition and guide treatment.
Hear when a new Respiratory Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.